Abstract
An activating mutation in codon 599 of BRAF has been identified in approximately 60% of human cutaneous nevi and melanomas, but not melanomas of mucosal origin. The purpose of this study was to determine if BRAF mutations occur in canine oral malignant melanomas. The canine BRAF gene was first cloned from normal canine testicular cDNA, and a novel previously unreported splice variant involving exon 5 was identified during this process. To screen canine melanoma samples for BRAF mutation in codon 599, cDNA and genomic DNA were isolated from canine malignant melanoma cell lines and primary tumor samples respectively, all from cases seen at the Veterinary Medical Teaching Hospital at the University of California, Davis. Polymerase chain reaction (PCR) was performed for exon 15 using primers based at the 5′ end of exon 15 and the 5′ end of intron 15 and the resultant products were directly sequenced. No mutations in codon 599 or exon 15 were identified in any of the 17 samples evaluated. However, all of the melanoma cell lines expressed BRAF and demonstrated high levels of basal ERK phosphorylation suggesting that dysregulation of this pathway is present. Therefore, similar to the case with human mucosal melanomas, canine oral malignant melanomas do not possess codon 599 BRAF mutations commonly identified in human cutaneous melanomas. This finding supports the notion that melanomas arising from non-sun-exposed sites exhibit distinct mechanisms of molecular transformation.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
JV Barnier C Papin A Eychene O Lecoq G Calothy (1995) ArticleTitleThe mouse B-raf gene encodes multiple protein isoforms with tissue-specific expression J Biol Chem 270 23381–23389
PJ Bergman J McKnight A Novosad S Charney J Farrelly et al. (2003) ArticleTitleLong-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial Clin Cancer Res 9 1284–1290
I Blackwood JM Dobson (1996) ArticleTitleRadiotherapy of oral malignant melanomas in dogs J Am Vet Med Assoc 209 98–102
MS Brose P Volpe M Feldman M Kumar I Rishi et al. (2002) ArticleTitleBRAF and RAS mutations in human lung cancer and melanoma Cancer Res 62 6997–7000
H Chong HG Vikis KL Guan (2003) ArticleTitleMechanisms of regulating the Raf kinase family Cell Signal 15 463–469
Y Cohen E Rosenbaum S Begum D Goldberg C Esche et al. (2004) ArticleTitleExon 15 BRAF mutations are uncommon in melanomas arising in nonsun-exposed sites Clin Cancer Res 10 3444–3447
EA Collisson A De H Suzuki SS Gambhir MS Kolodney (2003) ArticleTitleTreatment of metastatic melanoma with an orally available inhibitor of the Ras–Raf–MAPK cascade Cancer Res 63 5669–5673
H Davies GR Bignell C Cox P Stephens Edkins et al. (2002) ArticleTitleMutations of the BRAF gene in human cancer Nature 417 949–954
AS Dhillon W Kolch (2004) ArticleTitleOncogenic B-Raf mutations: crystal clear at last Cancer Cell 5 303–304
S Downing MB Chien PH Kass PE Moore CA London (2002) ArticleTitlePrevalence and importance of internal tandem duplications in exons 11 and 12 of c-kit in mast cell tumors of dogs Am J Vet Res 63 1718–1723
RH Edwards MR Ward H Wu CA Medina MS Brose et al. (2004) ArticleTitleAbsence of BRAF mutations in UV-protected mucosal melanomas J Med Genet 41 270–272
C Hagemann UR Rapp (1999) ArticleTitleIsotype-specific functions of Raf kinases Exp Cell Res 253 34–46
HJ Harvey EG MacEwen D Braun AK Patnaik SJ Withrow et al. (1981) ArticleTitlePrognostic criteria for dogs with oral melanoma J Am Vet Med Assoc 178 580–582
GS Hogge JK Burkhader J Culp MR Albertini RR Dubielzig et al. (1999) ArticleTitlePreclinical development of human granulocyte–macrophage colony–stimulating factor-transfected melanoma cell vaccine using established canine cell lines and normal dogs Cancer Gene Ther 6 26–36
SJ Hotte HW Hirte (2002) ArticleTitleBAY 43−9006: early clinical data in patients with advanced solid malignancies Curr Pharm Des 8 2249–2253
ET Kimura MN Nikiforova Z Zhu JA Knauf YE Nikiforov et al. (2003) ArticleTitleHigh prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC–RAS–BRAF signaling pathway in papillary thyroid carcinoma Cancer Res 63 1454–1457
R Kumar S Angelini E Snellman K Hemminki (2004) ArticleTitleBRAF mutations are common somatic events in melanocytic nevi J Invest Dermatol 122 342–348
JF Lyons S Wilhelm B Hibner G Bollag et al. (2001) ArticleTitleDiscovery of a novel Raf kinase inhibitor Endocr Relat Cancer 8 219–225
EG MacEwen AK Patnaik HJ Harvey AA Hayes R Matus (1986) ArticleTitleCanine oral melanoma: comparison of surgery versus surgery plus Corynebacterium parvum Cancer Invest 4 397–402
EG MacEwen ID Kurzman DM Vail RR Dubielzig K Everlith et al. (1999) ArticleTitleAdjuvant therapy for melanoma in dogs: results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and granulocyte macrophage colony-stimulating factor Clin Cancer Res 5 4249–4258
KE Mercer CA Pritchard (2003) ArticleTitleRaf proteins and cancer: B-Raf is identified as a mutational target Biochim Biophys Acta 1653 25–40
MN Nikiforova ET Kimura M Gandhi PW Biddinger JA Knawf et al. (2003) ArticleTitleBRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas J Clin Endocrinol Metab 88 5399–5404
E O’Neill W Kolch (2004) ArticleTitleConferring specificity on the ubiquitous Raf/MEK signalling pathway Br J Cancer 90 283–288
C Peyssonnaux A Eychene (2001) ArticleTitleThe Raf/MEK/ERK pathway: new concepts of activation Biol Cell 93 53–62
H Rajagopalan A Bardelli C Lengauer KW Kinzler B Vogelstein et al. (2002) ArticleTitleTumorigenesis: RAF/RAS oncogenes and mismatch-repair status Nature 418 934
KM Rassnick DM Ruslander SM Cotter R Al-Sarraf DS Bruyette et al. (2001) ArticleTitleUse of carboplatin for treatment of dogs with malignant melanoma: 27 cases (1989–2000) J Am Vet Med Assoc 218 1444–1448
D Rimoldi S Salvi D Lienard FJ Lejeune D Speiser et al. (2003) ArticleTitleLack of BRAF mutations in uveal melanoma Cancer Res 63 5712–5715
K Satyamoorthy G Li MR Gerrero MS Brose P Volpe et al. (2003) ArticleTitleConstitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation Cancer Res 63 756–759
D Stramberg D Voliotis JG Moeller RA Hilger H Richly et al. (2002) ArticleTitleResults of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43−9006 in patients with solid tumors Int J Clin Pharmacol Ther 40 580–581
PT Wan MJ Garnett SM Roe S Lee D Niculescu–Duvaz et al. (2004) ArticleTitleMechanism of activation of the RAF–ERK signaling pathway by oncogenic mutations of B-RAF Cell 116 855–867
C Wellbrock L Ogilvie D Hedley M Karasarides J Martin et al. (2004) ArticleTitleV599EB-RAF is an oncogene in melanocytes Cancer Res 64 2338–2342
S Withrow EG MacEwen (2001) Small Animal Clinical Oncology W.B. Saunders Co. Philadelphia
ST Yuen H Davies TL Chan JW Ho GR Bignell et al. (2002) ArticleTitleSimilarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia Cancer Res 62 6451–6455
Acknowledgments
Funding for this work was provided by the Center for Companion Animal Health at the University of California, Davis.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Shelly, S., Chien, M.B., Yip, B. et al. Exon 15 BRAF mutations are uncommon in canine oral malignant melanomas. Mamm Genome 16, 211–217 (2005). https://doi.org/10.1007/s00335-004-2441-x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s00335-004-2441-x